Comparative Pharmacology
Head-to-head clinical analysis: GONAL F versus MENOPUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONAL F versus MENOPUR.
GONAL-F vs MENOPUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and estrogen production in females and spermatogenesis in males.
Menotropins (MENOPUR) contain follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, which stimulate ovarian follicular growth and maturation in women, and spermatogenesis in men with hypogonadotropic hypogonadism.
Subcutaneous injection: 75-300 IU once daily for follicular stimulation; individualized based on response.
225 IU subcutaneously or intramuscularly once daily starting on day 2-3 of cycle, adjusted after 5 days based on response; maximum daily dose 450 IU.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 16–32 hours) following subcutaneous administration. This supports once-daily dosing.
The terminal elimination half-life is approximately 30-40 hours for FSH activity, reflecting the prolonged effect on follicular development; clinical dosing is adjusted based on response.
Primarily renal (hepatic metabolism and biliary excretion are minor routes). Approximately 80% of the dose is excreted in urine, with less than 20% in feces.
Primarily renal excretion of unchanged drug and metabolites; approximately 80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Category C
Category C
Gonadotropin
Gonadotropin